FCI in Post-operative Low Grade Gliomas

NCT ID: NCT06294418

Last Updated: 2024-03-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-15

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this pilot study is to explore the utility of a new imaging technique, called Field Cycling Imaging (FCI), in postoperative low grade gliomas.

The main question it aims to answer is if FCI can differentiate subtypes of low grade gliomas. Participants will have one FCI scan.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Standard clinical magnetic resonance imaging (MRI) is the mainstay of diagnosis in brain lesions. It is a powerful imaging technique for the non-invasive investigation of the brain and has been an incredibly successful technology since its commercialisation in the 1980s largely due to its excellent spatial resolution and ability to distinguish multiple tissues in multiple planes. When exogenous contrast agents are used, MRI can demonstrate the breakdown of the blood-brain barrier and provide additional physiological information.

However, standard MRI has limitations in determining the subtypes of tumours, which originate from different cells and therefore contain differing types of proteins. The aim of this project is to establish if there is a difference in the relaxometry (i.e., loss of MRI signal over time) characteristics of different brain lesions using Field Cycling Imaging (FCI), which is a new technology being developed at the University of Aberdeen.

FCI combines the use of a moderately high magnetic field with the ability to probe low magnetic fields so that one can preserve image resolution while also exploiting the high contrast present at low magnetic fields. This provides quantitative data on the molecular dynamics in the tissues, completely non-invasively.

For this study, the research team will use FCI to try to establish if there is a difference in the relaxometry characteristics of different low-grade gliomas. Ten patients with postoperative low grade glioma will be included. Each participant will be asked to undergo one FCI scan only. FCI images will be acquired on dedicated equipment, specifically built for the purpose of imaging human volunteers and patients. Participants will carry on receiving their routine clinical care before and after their scan.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low grade glioma

Patients with postoperative low grade glioma will undergo one FCI scan.

Group Type EXPERIMENTAL

Field Cycling Imaging (FCI)

Intervention Type DEVICE

FCI scan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Field Cycling Imaging (FCI)

FCI scan

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with post operative low-grade glioma.
* Capacity to give informed consent.
* Capacity to co-operate with the scanning procedures and duration.
* Age 16 and above.
* Participants who can pass through a 50 cm-diameter circular hoop to ensure they will be able to fit inside the scanner.
* Participants who meet the safety criteria for undergoing an MRI scan.
* Participants must be mobile enough to be positioned onto the FCI scanner couch.

Exclusion Criteria

* MRI-incompatible conditions, as detected in the MRI safety screening form.
* Restrictions to mobility that would prevent the correct positioning in the scanner by trained research radiographer (e.g., severe kyphosis).
* Participants who are unable to give fully informed consent.
* Women who are pregnant.
* Participants who are unable to understand or communicate in English.
* Patients who suffer from claustrophobia.
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aberdeen

OTHER

Sponsor Role collaborator

NHS Grampian

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arnab K Rana, Dr

Role: STUDY_CHAIR

University of Aberdeen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aberdeen Royal Infirmary

Aberdeen, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Celia G Alvarez Campano, Dr

Role: CONTACT

+441224437828

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Arnab K Rana, Dr

Role: primary

+441224438363

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1-037-23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Enhanced Detection in Glioma Excision
NCT04556929 TERMINATED NA